OptiBiotix Health (LSE:OPTI) has sought to reassure shareholders following recent developments at SkinBioTherapeutics, confirming it has no plans to dispose of its 5.64% holding in that business or its stake in ProBiotix Health. Management stated that recent share price volatility does not affect its long-term strategic investments and reiterated confidence in OptiBiotix’s own operational trajectory.
The group reported an unaudited cash balance of just over £1 million as of 31 December 2025, compared with £739,000 a year earlier, and indicated that it does not anticipate the need for additional fundraising at present. Focus remains on driving revenue growth, expanding margins and lowering overheads across divisions. More than £800,000 of orders for 2026 have already been secured, while ecommerce activities — including Amazon and Chinese distribution channels — are either profitable or nearing breakeven.
The board highlighted continued traction from its first-generation product portfolio and progress in launching next-generation offerings. In particular, developments within the SweetBiotix range and a significant 24-metric-tonne order from partner Meelung were cited as notable milestones. Leadership emphasised that tighter cost controls and clearer regional profit-and-loss accountability have positioned the company more strongly operationally, even amid broader market uncertainty.
Despite commercial progress, the company’s outlook remains tempered by ongoing losses and sustained cash outflows, alongside weak share price momentum and a prolonged technical downtrend. A debt-free balance sheet offers some resilience, though valuation remains challenging given negative earnings and the absence of dividend support.
More about OptiBiotix Health
OptiBiotix Health is a UK-based life sciences business focused on microbiome science and the development of ingredients designed to prevent and manage chronic health conditions. Its portfolio includes prebiotic platforms such as SlimBiome, WellBiome, SweetBiotix and other microbiome modulators. The group also holds equity interests providing exposure to skincare innovations through SkinBioTherapeutics and probiotic solutions via ProBiotix Health, targeting global consumer healthcare markets.
Leave a Reply